Evidence map›Paper›PMID 32576912›Full record

ArticleScientific reports2020

Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis.

C Carlomagno, P I Banfi, A Gualerzi, S Picciolini, E Volpato, M Meloni, A Lax, E Colombo, N Ticozzi, F Verde and 2 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04583306 unknown statusnot on this map

Characterization of the COVID-19 Raman Signature of Saliva as a Potential Tool for the Fast Discrimination of SARS-CoV-2 Infection and Severity

Typeobservational_patient_registrySponsorFondazione Don Carlo Gnocchi ETSRan2020 to 2022Enrolled120ConditionsCovid19ArmsRaman analysis of saliva, characterization of the Raman database and building of the classification model
NCT04628962 unknown statusnot on this mapstarted 2022, after this paper: background citation

Raman Analysis of Saliva From COPD Patients as New Biomarker: AI-based Point-of-care for the Disease Monitoring and Management

TypeobservationalSponsorFondazione Don Carlo Gnocchi ETSRan2022 to 2025Enrolled250ConditionsChronic Obstructive Pulmonary DiseaseArmsCollection and Raman analysis of saliva for the database
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Biosensors · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Raman Spectroscopy as a Tool to Study the Pathophysiology of Brain Diseases.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

C CarlomagnoIRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.
P I BanfiIRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.
A GualerziIRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.ORCID http://orcid.org/0000-0003-2996-5714
S PiccioliniIRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.
E VolpatoIRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.
M MeloniIRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.
A LaxIRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.
E ColomboIstituto Auxologico Italiano, IRCCS Department of Neurology and Laboratory of Neuroscience, 20149, Milan, Italy.
N TicozziIstituto Auxologico Italiano, IRCCS Department of Neurology and Laboratory of Neuroscience, 20149, Milan, Italy.ORCID http://orcid.org/0000-0001-5963-7426
F VerdeIstituto Auxologico Italiano, IRCCS Department of Neurology and Laboratory of Neuroscience, 20149, Milan, Italy.
V SilaniIstituto Auxologico Italiano, IRCCS Department of Neurology and Laboratory of Neuroscience, 20149, Milan, Italy.ORCID http://orcid.org/0000-0002-7698-3854
M BedoniIRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy. mbedoni@dongnocchi.it.ORCID http://orcid.org/0000-0003-2618-3661
Don Carlo Gnocchi Foundation · ITUniversity of Milan · ITIRCCS Istituto Auxologico Italiano · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease leading to progressive and irreversible muscle atrophy. The diagnosis of ALS is time-consuming and complex, with the clinical and neurophysiological evaluation accompanied by monitoring of progression and a long procedure for the discrimination of similar neurodegenerative diseases. The delayed diagnosis strongly slows the potential development of adequate therapies and the time frame for a prompt intervention. The discovery of new biomarkers could improve the disease diagnosis, as well as the therapeutic and rehabilitative effectiveness and monitoring of the pathological progression. In this work saliva collected from 19 patients with ALS, 10 affected by Parkinson's disease, 10 affected by Alzheimer's disease and 10 healthy subjects, was analysed using Raman spectroscopy, optimizing the parameters for detailed and reproducible spectra. The statistical multivariate analysis of the data revealed a significant difference between the groups, allowing the discrimination of the disease onset. Correlation of Raman data revealed a direct relationship with paraclinical scores, identifying multifactorial biochemical modifications related to the pathology. The proposed approach showed a promising accuracy in ALS onset discrimination, using a fast and sensitive procedure that can make more efficient the diagnostic procedure and the monitoring of therapeutic and rehabilitative processes in ALS.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyotrophic Lateral SclerosisBiomarkersDisease ProgressionHumansMaleMiddle AgedParkinson DiseaseSalivaBiomarkers

Identifiers

PMID32576912
PMCPMC7311476
OpenAlexW3036689436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.